Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fructose SCHEMBL27535426 | 1.00 | CYP2C9 (0.45) | CYP2C9TSHRPDE4ALMNAL3MBTL1 | |
| Fructose SCHEMBL4432524 | 1.00 | CYP2C9 (0.45) | CYP2C9TSHRPDE4ALMNAL3MBTL1 | |
| Fructose SCHEMBL6397124 | 1.00 | CYP2C9 (0.45) | CYP2C9TSHRPDE4ALMNAL3MBTL1 | |
| Tagatose SCHEMBL8749463 | 1.00 | CYP2C9 (0.45) | CYP2C9TSHRPDE4ALMNAL3MBTL1 | |
| Fructose SCHEMBL3945244 | 1.00 | CYP2C9 (0.45) | CYP2C9TSHRPDE4ALMNAL3MBTL1 | |
| Fructose SCHEMBL7256729 | 1.00 | CYP2C9 (0.45) | CYP2C9TSHRPDE4ALMNAL3MBTL1 | |
| Tagatose SCHEMBL8848540 | 1.00 | CYP2C9 (0.45) | CYP2C9TSHRPDE4ALMNAL3MBTL1 | |
| Fructose SCHEMBL22117547 | 1.00 | CYP2C9 (0.45) | CYP2C9TSHRPDE4ALMNAL3MBTL1 | |
| Fructose SCHEMBL22117548 | 1.00 | CYP2C9 (0.45) | CYP2C9TSHRPDE4ALMNAL3MBTL1 | |
| Fructose SCHEMBL8106542 | 0.98 | CYP2C9 (0.44) | CYP2C9TSHRPDE4ALMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9056116-B2 | Liquid ganaxolone formulations and methods for the making and use thereof | MARINUS PHARMACEUTICALS (US) | 2015-06-16 | — | — | US | disclosed |
| US-20130287851-A1 | LIQUID GANAXOLONE FORMULATIONS AND METHODS FOR THE MAKING AND USE THEREOF | IMMEDICA PHARMA US INC. | 2013-10-31 | — | — | US | disclosed |
| US-7153971-B2 | Contacting a carbohydrate with an amine to produce amino tetrahydroxy carbohydrate, protecting two hydroxy groups of tetrahydroxy carbohydrate, forming hydroxy heterocyclic-spiro moiety by reacting with activated carbonate, oxidizing OH | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2006-12-26 | — | — | US | disclosed |
| EP-1317460-A4 | COMPOUNDS CONTAINING OXAZOLIDINONE MOIETY AND USES THEREOF | UNIV COLORADO STATE RES FOUND (US) | 2005-04-20 | — | — | EP | disclosed |
| EP-1071676-A4 | KINETIC RESOLUTION OF OLEFINS | UNIV COLORADO STATE RES FOUND (US) | 2004-09-29 | — | — | EP | disclosed |
| US-20040039209-A1 | Compounds containing oxazolidinone moiety and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2004-02-26 | — | — | US | disclosed |
| EP-1021426-B1 | CATALYTIC ASYMMETRIC EPOXIDATION | UNIV COLORADO STATE RES FOUND (US) | 2003-09-17 | — | — | EP | disclosed |
| EP-1317460-A1 | COMPOUNDS CONTAINING OXAZOLIDINONE MOIETY AND USES THEREOF | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2003-06-11 | — | — | EP | disclosed |
| US-6409769-B1 | ASYMMETRIC EPOXIDATION OF THE STEREOISOMERS WITH AN OXIDIZING AGENT AND A CHIRAL KETONE PRODUCING AN EPOXIDE OF AT LEAST ONE STEREOISOMER AT A RELATIVELY HIGHER RATE THAN AN EPOXIDE OF ANOTHER STEREOISOMER OF THE COMPOUND. | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION | 2002-06-25 | — | — | US | disclosed |
| WO-2002018391-A1 | COMPOUNDS CONTAINING OXAZOLIDINONE MOIETY AND USES THEREOF | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2002-03-07 | — | — | WO | disclosed |
| US-6348608-B1 | ADDING OXIDIZING AGENT TO REACTION SOLUTION COMPRISING CHIRAL CYCLIC ENANTIOMERICALLY ENRICHED KETONE AND OLEFIN UNDER CONDITIONS EFFECTIVE TO GENERATE ENANTIOMERICALLY ENRICHED EPOXIDE, SEPARATING EPOXIDE FROM REACTION SOLUTION | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION | 2002-02-19 | — | — | US | disclosed |
| EP-1071676-A1 | KINETIC RESOLUTION OF OLEFINS | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2001-01-31 | — | — | EP | disclosed |
| EP-1021426-A4 | CATALYTIC ASYMMETRIC EPOXIDATION | UNIV COLORADO STATE RES FOUND (US) | 2000-07-26 | — | — | EP | disclosed |
| EP-1021426-A1 | CATALYTIC ASYMMETRIC EPOXIDATION | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-1999052886-A1 | KINETIC RESOLUTION OF OLEFINS | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1999-10-21 | — | — | WO | disclosed |
| WO-1998015544-A1 | CATALYTIC ASYMMETRIC EPOXIDATION | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1998-04-16 | — | — | WO | disclosed |
| EP-0758250-A1 | TEXAPHYRIN SOLID-SUPPORTS AND DEVICES | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1997-02-19 | — | — | EP | disclosed |
| WO-1995029702-A1 | TEXAPHYRIN SOLID-SUPPORTS AND DEVICES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1995-11-09 | — | — | WO | disclosed |
| WO-1994009003-A1 | SAPPHYRIN DERIVATIVES, CONJUGATES AND POLYMERS THEREOF AND EXPANDED PORPHYRIN CHROMATOGRAPHIC SUPPORTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1994-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039209-A1 | Compounds containing oxazolidinone moiety and uses thereof | OXER1, OXA1L, AOX1 | CYP2C9 110/4885TSHR 4087/4885PDE4A 3079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.